The settlement comes two years after the SEC began looking into claims at Theranos that it had developed potentially revolutionary blood-testing technology.
“When we saw what the kids were going through and the grief of the parents and the kids who were killed in Parkland, we felt we needed to do something,” said the company's CEO.
Purdue’s promotions exaggerated the drug’s safety and risks of addiction, leaning heavily on one sentence used by sales reps to market the drug to doctors.
